Frontlight ResearchEarly access
CompletedPhase 4
N-acetylcysteine for the treatment of cannabis dependence: working mechanisms
Key facts
- Who runs it
- UZ Brussel
- Where
- Belgium1 site in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 50 people enrolled
- Started
- 15 Jan 2025
- Ended
- 17 Feb 2026
- Type of study
- Interventional
- Record updated
- 15 January 2025
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Males, aged 18-45 years
- Current DSM-IV diagnosis of cannabis dependence
- >1 week detoxified and abstinent
- Able to provide written informed consent and to comply with study procedures
- Dutch speaking (Dutch as primary language)
Who cannot take part
- Known hypersensitivity or allergy to n-acetylcysteine, or receiving chronic therapy with medication that could interact adversely with n-acetylcysteine within 30 days prior to randomization (i.e., nitroglycerin, ACE inhibitors or antihypertensive drugs, anti-coagulants)
- History of any major internal disease (including diabetes, cardiovascular disease, lung disease, liver or kidney disease)
- An active or any history of neurological disorder, including but not limited to seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches
- An active or a history of a psychiatric disorder including, but not limited to, depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders
- Currently dependent on any substance other than cannabis, alcohol or nicotine
- Asthma
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the working mechanisms of N-acetylcysteine for the treatment of cannabis dependence
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Record updated
- 15 January 2025